CXCR4 and neoplasm: Taken together, these observations demonstrate that huCAR19 NK cells augmented with CXCR4 are able to eradicate CD19+ tumor cells in a CAR-dependent manner, have significantly enhanced migration ability, and retain their functional activity post-migration.